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It is truly remarkable that patients whose HIV is controlled 
on antiviral therapy will have a life-expec tation similar to 
that of the general population. However, little research 
has been done on what the quality of this life might be. 
In The Lancet HIV, Alec Miners and colleagues1 research 
health related quality of life (HRQoL) of people with HIV 
in the era of combination ART. The authors point out 
that HIV positive people doing well on treatment have a 
signiﬁ cantly reduced HRQoL compared with that in the 
general population. It is interesting to speculate why this 
might be, and what could be done about it. 
Perhaps these ﬁ ndings are not that surprising, in 
view that the study compares a group of people with a 
long-term chronic illness, many of whom come from a 
background of risk behaviour, stigma, legal constraints, 
political suppression, and immigration, with the general 
public. In fact a similar eﬀ ect was seen in another chronic 
viral illness, hepatitis C infection, more than a decade ago 
with impairment in HRQoL relative to that in the general 
population.2 
Anxiety and depression are major factors aﬀ ecting 
HRQoL,3 and mental health or drug problems were 
possibly important factors before HIV infection that 
continue to have an important bearing. However, the 
stigma of becoming HIV positive and the signiﬁ cant 
losses of self-esteem, friendships, family support, and 
help, often at a young age around the time of diagnosis 
can cause adjustment disorders that may persist4 and 
might well have serious consequences.
Miner and colleagues’ study shows that the eﬀ ect on 
HRQoL was greatest for those diagnosed with HIV in 
the earlier years of the epidemic. That was a time when 
suppressive HIV treatment and long-term support 
networks were not contemplated and some patients 
might have presented with life-threatening illnesses, 
which have left them disabled. They could have also lost 
friends and partners, and lived through prolonged stigma 
and legislation against men who have sex with men 
(MSM).
By contrast, those diagnosed in more recent years 
might adjust better to an HIV diagnosis and potentially 
have a better HRQoL. They have the advantage of 
medicines that are easy to take with favourable side-
eﬀ ect proﬁ les and strong positive messages about 
transmittability, life expectancy, less stigma, increasing 
societal acceptance of being MSM, and better social 
networking for those with HIV facilitated by the internet.
This study showed that non-white females are also 
disadvantaged. Their HRQoL could be aﬀ ected by unequal 
access to care, poverty, unemployment, and stigma.5 
Some might have lost their partners and have children 
living with relatives in their countries of origin. This 
population often present late and their mental health 
needs might not be recognised.6 
Side-eﬀ ects of long-term medication that could aﬀ ect 
HRQoL are not captured in Miners and colleagues’ 
dataset. Efavirenz, one of the most common antivirals, 
has been associated with durable neuropsychiatric 
eﬀ ects,7 and a recent analysis has suggested it is 
associated with suicidality risk.8
Decreased HRQoL in HIV patients has been reported 
from several countries including China and Mexico; in 
South Africa the diﬀ erences between HIV positive and 
negative gold miners was dependent on the test used.9 
In a small study in Uganda people with HIV on ART had 
higher HRQoL and lower depression scores than did a 
general community sample.10 This diﬀ erence was possibly 
in part related to better access to health-care among 
those with HIV.
So what should be done to achieve acceptable HRQoL 
now that HIV is a chronic disease with the prospect of 
long-term survival? HRQoL is characterised by feelings 
of wellbeing, control, and autonomy, a positive self-
perception, a sense of belonging, participation in 
enjoyable and meaningful activity, and a positive view 
of the future.11 Awareness of quality issues to balance the 
focus on longevity could be a good start. Among adults 
with HIV and depression, improved access to high-quality 
mental-health treatment can improve important HRQoL 
outcomes.12
Whether HIV positive people have more HRQoL 
needs than any other group with long-term illnesses is 
unknown, and although this paper does not quantify the 
impact of HIV infection compared with other factors, it 
does highlight a signiﬁ cant problem. Health services will 
need to continue to adapt to ageing populations with 
chronic illnesses such as HIV and take note that access 
to appropriate mental health, social, and psychological 
support services may actually reduce unnecessary use of 
other health services by improving HRQoL. 
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